# Russell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 2 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 2 | 0.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 11 | 6.9 | 158.3 | (78.9-283.2) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 6 | 1.7 | 362.9 | (132.5-789.9) |  | Female | 2 | 0.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 4 | 5.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 1.0 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 2.8 | nc | (nc-nc) |  | Male | 18 | 20.8 | 86.4 | (51.2-136.6) |
| Female | 3 | 3.3 | nc | (nc-nc) |  | Female | 29 | 22.7 | 127.5 | (85.4-183.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

265

# Rutland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 6.7 | 74.9 | (24.1-174.8) |  | Male | 6 | 4.7 | 126.4 | (46.1-275.1) |
| Female | 2 | 2.1 | nc | (nc-nc) |  | Female | 0 | 3.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 2 | 1.5 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 5 | 4.3 | 115.2 | (37.1-268.9) |
| Female | 40 | 29.9 | 133.8 | (95.6-182.2) |  | Female | 3 | 3.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 3.9 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 0 | 1.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 8.2 | 122.7 | (58.7-225.6) |  |  |  |  |  |  |
| Female | 7 | 6.7 | 104.4 | (41.8-215.2) |  | Female | 2 | 2.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 1.9 | nc | (nc-nc) |  | Male | 2 | 2.6 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 3 | 2.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 26 | 25.4 | 102.3 | (66.8-149.9) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 4.6 | nc | (nc-nc) |  | Male | 0 | 1.7 | nc | (nc-nc) |
| Female | 0 | 2.2 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.1 | nc | (nc-nc) |  | Male | 3 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 3.0 | 197.3 | (72.0-429.5) |  | Male | 0 | 2.3 | nc | (nc-nc) |
| Female | 2 | 1.9 | nc | (nc-nc) |  | Female | 3 | 6.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 2.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 6 | 6.6 | 91.1 | (33.3-198.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 17 | 12.2 | 139.6 | (81.3-223.6) |  | Male | 99 | 97.9 | 101.1 | (82.2-123.1) |
| Female | 9 | 11.3 | 79.8 | (36.4-151.5) |  | Female | 88 | 93.0 | 94.6 | (75.9-116.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

266

# Salem

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 35 | 34.8 | 100.5 | (70.0-139.7) |  | Male | 32 | 23.5 | 136.3 | (93.2-192.5) |
| Female | 11 | 16.5 | 66.6 | (33.2-119.2) |  | Female | 22 | 23.3 | 94.3 | (59.1-142.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 11 | 7.6 | 144.1 | (71.8-257.8) |  | Male | 4 | 7.3 | nc | (nc-nc) |
| Female | 2 | 7.4 | nc | (nc-nc) |  | Female | 13 | 7.5 | 173.2 | (92.1-296.2) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 1.2 | nc | (nc-nc) |  | Male | 30 | 21.2 | 141.4 | (95.4-201.9) |
| Female | 169 | 180.0 | 93.9 | (80.3-109.1) |  | Female | 21 | 23.3 | 90.3 | (55.9-138.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 22 | 17.9 | 123.1 | (77.1-186.4) |
| Female | 5 | 6.3 | 79.9 | (25.8-186.6) |  | Female | 14 | 9.8 | 143.1 | (78.2-240.1) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 42 | 39.8 | 105.5 | (76.0-142.5) |  |  |  |  |  |  |
| Female | 36 | 48.9 | 73.7 | (51.6-102.0) |  | Female | 9 | 15.8 | 56.9 | (26.0-108.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 12 | 9.2 | 131.0 | (67.6-228.9) |  | Male | 10 | 12.8 | 78.2 | (37.4-143.9) |
| Female | 6 | 3.2 | 188.7 | (68.9-410.8) |  | Female | 14 | 16.9 | 83.1 | (45.4-139.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 3.5 | nc | (nc-nc) |  | Male | 145 | 112.2 | 129.2 | (109.1-152.1) |
| Female | 9 | 3.3 | 276.6 | (126.2-525.2) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 26 | 20.8 | 125.1 | (81.7-183.3) |  | Male | 16 | 8.7 | 184.3 | (105.3-299.3) |
| Female | 17 | 14.4 | 118.2 | (68.8-189.2) |  | Female | 2 | 6.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 5.4 | nc | (nc-nc) |  | Male | 6 | 6.9 | 87.1 | (31.8-189.7) |
| Female | 3 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 16 | 15.0 | 106.5 | (60.8-173.0) |  | Male | 11 | 10.4 | 106.2 | (52.9-190.0) |
| Female | 16 | 13.7 | 117.0 | (66.9-190.1) |  | Female | 45 | 35.3 | 127.6 | (93.0-170.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 14 | 12.8 | 109.5 | (59.8-183.8) |  |  |  |  |  |  |
| Female | 2 | 5.5 | nc | (nc-nc) |  | Female | 44 | 40.4 | 109.0 | (79.2-146.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 74 | 62.1 | 119.1 | (93.5-149.5) |  | Male | 566 | 470.9 | 120.2 | (110.5-130.5) |
| Female | 98 | 84.7 | 115.7 | (93.9-141.0) |  | Female | 613 | 615.3 | 99.6 | (91.9-107.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

267

# Salisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 12 | 9.9 | 121.2 | (62.5-211.7) |  | Male | 10 | 6.5 | 154.3 | (73.9-283.8) |
| Female | 4 | 3.2 | nc | (nc-nc) |  | Female | 3 | 4.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 2.0 | nc | (nc-nc) |  | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 1 | 1.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 6 | 5.8 | 102.7 | (37.5-223.6) |
| Female | 47 | 40.7 | 115.4 | (84.8-153.4) |  | Female | 8 | 4.6 | 172.8 | (74.4-340.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 14 | 5.2 | 270.7 | (147.9-454.2) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 3 | 2.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 15 | 10.8 | 138.3 | (77.3-228.1) |  |  |  |  |  |  |
| Female | 15 | 9.1 | 164.9 | (92.2-271.9) |  | Female | 7 | 3.4 | 205.7 | (82.4-423.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 2.7 | nc | (nc-nc) |  | Male | 5 | 3.7 | 135.4 | (43.6-315.9) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 6 | 3.2 | 187.1 | (68.3-407.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 28 | 36.2 | 77.3 | (51.3-111.7) |
| Female | 2 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 6.0 | 133.7 | (57.6-263.5) |  | Male | 3 | 2.4 | nc | (nc-nc) |
| Female | 4 | 3.1 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 4.0 | nc | (nc-nc) |  | Male | 1 | 2.6 | nc | (nc-nc) |
| Female | 2 | 2.6 | nc | (nc-nc) |  | Female | 8 | 7.3 | 109.2 | (47.0-215.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 3.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 11 | 9.5 | 116.4 | (58.0-208.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 21 | 18.4 | 114.0 | (70.5-174.3) |  | Male | 139 | 136.2 | 102.0 | (85.8-120.5) |
| Female | 28 | 17.6 | 159.3 | (105.8-230.2) |  | Female | 167 | 128.8 | 129.6 | (110.7-150.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

268

# Sandisfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 2.0 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 1 | 4.2 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 4.9 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 2 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 3.4 | nc | (nc-nc) |  | Male | 12 | 22.2 | 54.1 | (27.9-94.5) |
| Female | 3 | 1.8 | nc | (nc-nc) |  | Female | 9 | 13.2 | 68.1 | (31.1-129.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

269

# Sandwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 32 | 24.3 | 131.8 | (90.1-186.0) |  | Male | 19 | 15.5 | 122.9 | (74.0-192.0) |
| Female | 8 | 8.3 | 96.3 | (41.5-189.7) |  | Female | 15 | 11.7 | 128.4 | (71.8-211.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 10 | 4.6 | 218.0 | (104.4-401.0) |  | Male | 4 | 5.1 | nc | (nc-nc) |
| Female | 6 | 3.8 | 159.4 | (58.2-346.9) |  | Female | 1 | 3.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 17 | 13.8 | 123.1 | (71.7-197.1) |
| Female | 116 | 97.4 | 119.0 | (98.4-142.8) |  | Female | 13 | 11.9 | 109.2 | (58.1-186.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 11.9 | 83.7 | (40.1-154.0) |
| Female | 1 | 3.1 | nc | (nc-nc) |  | Female | 8 | 5.1 | 157.1 | (67.7-309.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 19 | 26.3 | 72.3 | (43.5-113.0) |  |  |  |  |  |  |
| Female | 20 | 24.1 | 83.0 | (50.7-128.1) |  | Female | 9 | 8.4 | 107.5 | (49.1-204.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 6.5 | 77.4 | (24.9-180.6) |  | Male | 14 | 8.8 | 159.3 | (87.0-267.3) |
| Female | 3 | 1.7 | nc | (nc-nc) |  | Female | 10 | 8.4 | 119.4 | (57.1-219.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  | Male | 94 | 80.3 | 117.1 | (94.7-143.3) |
| Female | 1 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 13.8 | 72.5 | (34.7-133.3) |  | Male | 6 | 5.9 | 101.9 | (37.2-221.7) |
| Female | 7 | 7.6 | 91.8 | (36.8-189.1) |  | Female | 4 | 3.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 3.8 | nc | (nc-nc) |  | Male | 2 | 2.7 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 9.7 | 102.8 | (49.2-189.0) |  | Male | 2 | 6.0 | nc | (nc-nc) |
| Female | 3 | 6.7 | nc | (nc-nc) |  | Female | 11 | 17.2 | 64.0 | (31.9-114.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 8.8 | 67.9 | (24.8-147.9) |  |  |  |  |  |  |
| Female | 1 | 2.8 | nc | (nc-nc) |  | Female | 24 | 22.5 | 106.6 | (68.3-158.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 30 | 44.0 | 68.1 | (46.0-97.3) |  | Male | 331 | 319.0 | 103.8 | (92.9-115.6) |
| Female | 44 | 44.9 | 98.0 | (71.2-131.5) |  | Female | 333 | 320.1 | 104.0 | (93.2-115.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

270

# Saugus

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 48 | 31.0 | 154.6 | (114.0-205.0) |  | Male | 18 | 20.0 | 90.1 | (53.4-142.4) |
| Female | 20 | 13.2 | 151.8 | (92.7-234.4) |  | Female | 20 | 17.4 | 115.1 | (70.3-177.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 5.8 | 85.7 | (27.6-200.1) |  | Male | 6 | 6.5 | 91.8 | (33.5-199.9) |
| Female | 8 | 5.5 | 146.0 | (62.9-287.8) |  | Female | 5 | 6.0 | 83.2 | (26.8-194.2) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 1.1 | nc | (nc-nc) |  | Male | 29 | 17.9 | 161.7 | (108.3-232.3) |
| Female | 147 | 143.8 | 102.2 | (86.4-120.1) |  | Female | 25 | 18.3 | 136.9 | (88.6-202.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 19 | 14.8 | 128.6 | (77.4-200.9) |
| Female | 4 | 4.5 | nc | (nc-nc) |  | Female | 6 | 7.7 | 78.2 | (28.6-170.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 48 | 33.5 | 143.5 | (105.8-190.2) |  |  |  |  |  |  |
| Female | 32 | 37.8 | 84.6 | (57.9-119.5) |  | Female | 5 | 12.4 | 40.5 | (13.0-94.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 13 | 8.1 | 161.3 | (85.8-275.8) |  | Male | 15 | 11.2 | 134.0 | (74.9-221.0) |
| Female | 4 | 2.6 | nc | (nc-nc) |  | Female | 15 | 13.4 | 112.1 | (62.7-185.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 2.2 | nc | (nc-nc) |  | Male | 79 | 96.8 | 81.6 | (64.6-101.7) |
| Female | 3 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 26 | 17.4 | 149.1 | (97.4-218.5) |  | Male | 6 | 7.6 | 79.3 | (28.9-172.5) |
| Female | 8 | 11.5 | 69.6 | (30.0-137.2) |  | Female | 2 | 5.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 7 | 4.8 | 145.9 | (58.4-300.5) |  | Male | 9 | 3.9 | 230.4 | (105.1-437.4) |
| Female | 0 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 17 | 12.4 | 137.3 | (79.9-219.9) |  | Male | 11 | 7.8 | 140.4 | (70.0-251.2) |
| Female | 3 | 10.3 | nc | (nc-nc) |  | Female | 20 | 24.4 | 82.1 | (50.1-126.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 17 | 11.0 | 155.1 | (90.3-248.3) |  |  |  |  |  |  |
| Female | 5 | 4.3 | 115.8 | (37.3-270.2) |  | Female | 28 | 32.8 | 85.3 | (56.7-123.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 66 | 56.0 | 117.8 | (91.1-149.9) |  | Male | 485 | 402.1 | 120.6 | (110.1-131.8) |
| Female | 88 | 69.8 | 126.1 | (101.1-155.4) |  | Female | 490 | 483.0 | 101.4 | (92.7-110.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

271

# Savoy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 2 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 3 | 3.1 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 3.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 1 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 1 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 2 | 0.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 1.6 | nc | (nc-nc) |  | Male | 7 | 12.1 | 58.0 | (23.2-119.4) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 10 | 9.6 | 103.7 | (49.6-190.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

272

# Scituate

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 21 | 22.9 | 91.6 | (56.7-140.1) |  | Male | 40 | 14.2 | 281.8 | (201.3-383.7) |
| Female | 12 | 8.0 | 149.5 | (77.2-261.2) |  | Female | 29 | 10.7 | 271.7 | (181.9-390.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 4.1 | 146.3 | (53.4-318.4) |  | Male | 7 | 4.6 | 151.2 | (60.6-311.5) |
| Female | 3 | 3.5 | nc | (nc-nc) |  | Female | 2 | 3.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 6 | 12.7 | 47.3 | (17.3-103.0) |
| Female | 89 | 89.5 | 99.4 | (79.8-122.4) |  | Female | 9 | 11.2 | 80.6 | (36.8-153.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 9 | 10.6 | 84.8 | (38.7-161.0) |
| Female | 1 | 2.8 | nc | (nc-nc) |  | Female | 7 | 4.7 | 147.6 | (59.1-304.2) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 21 | 24.4 | 86.0 | (53.2-131.5) |  |  |  |  |  |  |
| Female | 20 | 23.6 | 84.7 | (51.7-130.8) |  | Female | 8 | 7.6 | 104.7 | (45.1-206.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 5.8 | 120.0 | (48.1-247.3) |  | Male | 7 | 8.1 | 86.5 | (34.7-178.2) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 4 | 8.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 1.4 | nc | (nc-nc) |  | Male | 66 | 69.5 | 94.9 | (73.4-120.8) |
| Female | 1 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 12.3 | 56.7 | (22.7-116.9) |  | Male | 6 | 5.5 | 110.0 | (40.1-239.3) |
| Female | 6 | 7.0 | 85.2 | (31.1-185.4) |  | Female | 4 | 3.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 3.4 | nc | (nc-nc) |  | Male | 2 | 2.2 | nc | (nc-nc) |
| Female | 2 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 9.0 | 110.7 | (53.0-203.5) |  | Male | 1 | 5.2 | nc | (nc-nc) |
| Female | 7 | 6.4 | 109.4 | (43.8-225.5) |  | Female | 18 | 15.2 | 118.6 | (70.2-187.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 8 | 7.9 | 101.7 | (43.8-200.3) |  |  |  |  |  |  |
| Female | 3 | 2.7 | nc | (nc-nc) |  | Female | 21 | 20.0 | 104.9 | (64.9-160.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 33 | 40.4 | 81.6 | (56.2-114.7) |  | Male | 291 | 288.6 | 100.8 | (89.6-113.1) |
| Female | 45 | 41.9 | 107.4 | (78.3-143.7) |  | Female | 316 | 297.8 | 106.1 | (94.7-118.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

273

# Seekonk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 17.9 | 61.3 | (30.6-109.7) |  | Male | 6 | 11.5 | 52.3 | (19.1-113.8) |
| Female | 2 | 5.4 | nc | (nc-nc) |  | Female | 8 | 7.9 | 101.6 | (43.7-200.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 3.3 | nc | (nc-nc) |  | Male | 2 | 3.7 | nc | (nc-nc) |
| Female | 2 | 2.5 | nc | (nc-nc) |  | Female | 1 | 2.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 15 | 10.2 | 147.5 | (82.5-243.2) |
| Female | 37 | 65.6 | 56.4 | (39.7-77.7) |  | Female | 5 | 7.8 | 63.7 | (20.5-148.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 8.7 | nc | (nc-nc) |
| Female | 2 | 2.2 | nc | (nc-nc) |  | Female | 5 | 3.4 | 148.3 | (47.8-346.0) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 12 | 19.1 | 62.9 | (32.5-110.0) |  |  |  |  |  |  |
| Female | 9 | 15.7 | 57.2 | (26.1-108.6) |  | Female | 6 | 5.6 | 107.6 | (39.3-234.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 4.8 | nc | (nc-nc) |  | Male | 3 | 6.4 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 7 | 5.4 | 129.7 | (52.0-267.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 35 | 58.5 | 59.8 | (41.7-83.2) |
| Female | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 10.2 | 49.1 | (15.8-114.5) |  | Male | 2 | 4.3 | nc | (nc-nc) |
| Female | 0 | 5.1 | nc | (nc-nc) |  | Female | 1 | 2.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.8 | nc | (nc-nc) |  | Male | 0 | 2.0 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 7.1 | 84.8 | (31.0-184.7) |  | Male | 0 | 4.4 | nc | (nc-nc) |
| Female | 2 | 4.4 | nc | (nc-nc) |  | Female | 8 | 12.1 | 66.3 | (28.5-130.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 6.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.9 | nc | (nc-nc) |  | Female | 8 | 15.0 | 53.4 | (23.0-105.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 20 | 33.2 | 60.2 | (36.7-92.9) |  | Male | 141 | 234.4 | 60.2 | (50.6-70.9) |
| Female | 26 | 29.7 | 87.5 | (57.2-128.3) |  | Female | 139 | 213.4 | 65.1 | (54.8-76.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

274

# Sharon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 18.8 | 58.4 | (29.1-104.5) |  | Male | 13 | 12.4 | 105.2 | (56.0-179.9) |
| Female | 7 | 6.1 | 115.5 | (46.3-237.9) |  | Female | 17 | 9.3 | 181.9 | (105.9-291.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 3.8 | nc | (nc-nc) |  | Male | 6 | 4.0 | 149.4 | (54.6-325.2) |
| Female | 1 | 3.1 | nc | (nc-nc) |  | Female | 1 | 2.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 14 | 11.1 | 126.2 | (68.9-211.7) |
| Female | 88 | 78.4 | 112.3 | (90.1-138.3) |  | Female | 6 | 9.1 | 66.1 | (24.1-143.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 9.9 | 60.4 | (22.1-131.5) |
| Female | 0 | 2.7 | nc | (nc-nc) |  | Female | 1 | 4.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 11 | 21.4 | 51.4 | (25.6-92.0) |  |  |  |  |  |  |
| Female | 10 | 18.6 | 53.8 | (25.8-99.0) |  | Female | 5 | 6.6 | 76.0 | (24.5-177.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 5.2 | nc | (nc-nc) |  | Male | 9 | 7.0 | 128.6 | (58.7-244.2) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 8 | 6.2 | 129.3 | (55.7-254.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 64 | 65.9 | 97.1 | (74.7-124.0) |
| Female | 1 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 11.4 | 61.6 | (24.7-126.9) |  | Male | 4 | 4.7 | nc | (nc-nc) |
| Female | 8 | 6.0 | 134.4 | (57.9-264.8) |  | Female | 3 | 2.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 3.0 | nc | (nc-nc) |  | Male | 4 | 2.1 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 7.7 | 77.5 | (28.3-168.7) |  | Male | 9 | 5.1 | 177.7 | (81.1-337.4) |
| Female | 4 | 5.2 | nc | (nc-nc) |  | Female | 26 | 14.8 | 175.5 | (114.6-257.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 7.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 2.1 | nc | (nc-nc) |  | Female | 18 | 17.7 | 101.8 | (60.3-161.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 17 | 34.1 | 49.9 | (29.0-79.8) |  | Male | 217 | 256.2 | 84.7 | (73.8-96.7) |
| Female | 38 | 32.9 | 115.5 | (81.7-158.5) |  | Female | 265 | 250.1 | 106.0 | (93.6-119.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

275

# Sheffield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 5.1 | 97.2 | (31.3-226.8) |  | Male | 4 | 3.1 | nc | (nc-nc) |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 1 | 2.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 2 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 4 | 2.7 | nc | (nc-nc) |
| Female | 14 | 17.7 | 79.2 | (43.3-132.9) |  | Female | 1 | 2.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 2.3 | 220.8 | (71.2-515.3) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 3 | 0.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 5.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 4.2 | nc | (nc-nc) |  | Female | 1 | 1.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 0 | 1.8 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 1.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 21 | 16.1 | 130.4 | (80.7-199.3) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 2.7 | nc | (nc-nc) |  | Male | 2 | 1.2 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.9 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 1 | 2.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 6 | 4.2 | 142.1 | (51.9-309.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 9.3 | 54.0 | (17.4-126.1) |  | Male | 60 | 64.1 | 93.6 | (71.4-120.5) |
| Female | 11 | 8.5 | 129.6 | (64.6-232.0) |  | Female | 55 | 57.9 | 95.1 | (71.6-123.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

276

# Shelburne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 2.8 | nc | (nc-nc) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 3 | 1.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 2 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 11 | 11.7 | 94.0 | (46.9-168.3) |  | Female | 2 | 1.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 1.4 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 3.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 3.1 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 2 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 10 | 9.7 | 102.6 | (49.1-188.7) |
| Female | 1 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 3 | 1.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 7 | 2.7 | 255.4 | (102.3-526.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 5.2 | nc | (nc-nc) |  | Male | 35 | 37.2 | 94.0 | (65.4-130.7) |
| Female | 7 | 5.9 | 118.9 | (47.6-245.0) |  | Female | 45 | 39.6 | 113.5 | (82.8-151.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

277

# Sherborn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 10 | 5.4 | 183.8 | (88.0-338.0) |  | Male | 5 | 3.4 | 148.3 | (47.8-346.1) |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 2 | 2.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 2 | 3.0 | nc | (nc-nc) |
| Female | 18 | 19.5 | 92.3 | (54.7-145.8) |  | Female | 5 | 2.3 | 216.5 | (69.8-505.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 2.6 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 8 | 5.8 | 137.2 | (59.1-270.4) |  |  |  |  |  |  |
| Female | 3 | 4.8 | nc | (nc-nc) |  | Female | 5 | 1.7 | 300.1 | (96.7-700.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  | Male | 3 | 1.9 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 14 | 17.3 | 80.7 | (44.1-135.4) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 3.0 | nc | (nc-nc) |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 2.1 | nc | (nc-nc) |  | Male | 2 | 1.2 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 4 | 3.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 4 | 4.4 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 9.7 | 51.8 | (16.7-120.9) |  | Male | 61 | 69.6 | 87.6 | (67.0-112.6) |
| Female | 5 | 8.9 | 56.4 | (18.2-131.7) |  | Female | 54 | 63.4 | 85.2 | (64.0-111.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

278

# Shirley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 14 | 6.0 | 231.8 | (126.6-389.0) |  | Male | 2 | 4.8 | nc | (nc-nc) |
| Female | 6 | 2.0 | 292.8 | (106.9-637.3) |  | Female | 1 | 3.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  | Male | 3 | 1.4 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 8 | 4.3 | 188.1 | (81.0-370.7) |
| Female | 28 | 25.6 | 109.2 | (72.6-157.9) |  | Female | 2 | 3.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 3.9 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 3 | 1.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 12 | 7.9 | 152.3 | (78.6-266.0) |  |  |  |  |  |  |
| Female | 7 | 5.9 | 117.8 | (47.2-242.8) |  | Female | 2 | 2.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 1.8 | nc | (nc-nc) |  | Male | 2 | 2.4 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 2 | 2.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 29 | 22.6 | 128.3 | (85.9-184.2) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 4.5 | 156.1 | (62.5-321.6) |  | Male | 0 | 1.7 | nc | (nc-nc) |
| Female | 3 | 2.0 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 1 | 1.8 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 2.9 | nc | (nc-nc) |  | Male | 2 | 2.6 | nc | (nc-nc) |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 4 | 4.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 2.7 | 259.6 | (104.0-534.8) |  |  |  |  |  |  |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 12 | 5.8 | 208.2 | (107.5-363.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 17 | 11.3 | 150.0 | (87.4-240.3) |  | Male | 122 | 93.4 | 130.6 | (108.4-155.9) |
| Female | 10 | 11.4 | 87.7 | (42.0-161.3) |  | Female | 91 | 82.4 | 110.5 | (89.0-135.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

279

# Shrewsbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 42 | 36.7 | 114.5 | (82.5-154.8) |  | Male | 18 | 23.7 | 76.0 | (45.0-120.2) |
| Female | 12 | 12.3 | 97.8 | (50.5-170.9) |  | Female | 22 | 17.8 | 123.7 | (77.5-187.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 7.4 | 67.9 | (21.9-158.4) |  | Male | 10 | 7.6 | 131.0 | (62.7-240.9) |
| Female | 0 | 5.8 | nc | (nc-nc) |  | Female | 4 | 5.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 1.3 | nc | (nc-nc) |  | Male | 25 | 21.4 | 116.6 | (75.5-172.2) |
| Female | 165 | 144.7 | 114.0 | (97.3-132.8) |  | Female | 15 | 17.7 | 85.0 | (47.5-140.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 12 | 17.9 | 67.2 | (34.7-117.4) |
| Female | 5 | 5.1 | 98.7 | (31.8-230.2) |  | Female | 4 | 7.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 44 | 40.5 | 108.6 | (78.9-145.8) |  |  |  |  |  |  |
| Female | 32 | 36.9 | 86.8 | (59.3-122.5) |  | Female | 14 | 12.2 | 114.4 | (62.5-192.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 9.5 | 83.9 | (36.1-165.3) |  | Male | 9 | 13.2 | 68.3 | (31.2-129.7) |
| Female | 6 | 2.4 | 247.7 | (90.5-539.2) |  | Female | 10 | 12.5 | 80.3 | (38.4-147.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 2.9 | nc | (nc-nc) |  | Male | 128 | 115.8 | 110.6 | (92.2-131.5) |
| Female | 4 | 2.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 24 | 21.0 | 114.3 | (73.2-170.1) |  | Male | 3 | 8.9 | nc | (nc-nc) |
| Female | 7 | 11.3 | 62.2 | (24.9-128.1) |  | Female | 6 | 5.0 | 119.3 | (43.6-259.8) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 5.5 | nc | (nc-nc) |  | Male | 4 | 5.2 | nc | (nc-nc) |
| Female | 0 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 12 | 15.2 | 78.9 | (40.7-137.8) |  | Male | 16 | 9.7 | 164.5 | (94.0-267.1) |
| Female | 11 | 10.3 | 106.6 | (53.1-190.8) |  | Female | 19 | 28.0 | 67.8 | (40.8-105.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 13 | 12.9 | 100.9 | (53.6-172.5) |  |  |  |  |  |  |
| Female | 3 | 4.0 | nc | (nc-nc) |  | Female | 31 | 31.1 | 99.6 | (67.7-141.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 63 | 65.0 | 96.9 | (74.5-124.0) |  | Male | 492 | 480.1 | 102.5 | (93.6-112.0) |
| Female | 66 | 65.1 | 101.4 | (78.4-129.0) |  | Female | 475 | 477.1 | 99.6 | (90.8-108.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

280

# Shutesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 2 | 0.7 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 8 | 9.0 | 88.5 | (38.1-174.4) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 2.0 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 3 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 6.8 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 2 | 1.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 3 | 2.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 3.0 | nc | (nc-nc) |  | Male | 11 | 24.4 | 45.1 | (22.5-80.8) |
| Female | 2 | 3.7 | nc | (nc-nc) |  | Female | 22 | 28.6 | 76.8 | (48.1-116.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

281

# Somerset

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 32 | 26.2 | 122.1 | (83.5-172.4) |  | Male | 7 | 15.7 | 44.5 | (17.8-91.8) |
| Female | 13 | 10.0 | 130.3 | (69.3-222.9) |  | Female | 10 | 11.9 | 83.9 | (40.2-154.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 4.4 | 113.6 | (36.6-265.2) |  | Male | 0 | 5.1 | nc | (nc-nc) |
| Female | 3 | 3.8 | nc | (nc-nc) |  | Female | 6 | 4.4 | 137.1 | (50.1-298.4) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 13 | 14.1 | 92.5 | (49.2-158.2) |
| Female | 79 | 98.0 | 80.6 | (63.8-100.4) |  | Female | 16 | 13.2 | 121.6 | (69.5-197.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 11.2 | 71.5 | (30.8-140.9) |
| Female | 0 | 2.9 | nc | (nc-nc) |  | Female | 7 | 5.4 | 129.5 | (51.9-266.9) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 28 | 26.9 | 104.1 | (69.1-150.4) |  |  |  |  |  |  |
| Female | 34 | 28.1 | 121.0 | (83.8-169.0) |  | Female | 7 | 8.5 | 82.4 | (33.0-169.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 6.4 | 109.4 | (43.8-225.3) |  | Male | 10 | 9.0 | 110.7 | (53.0-203.6) |
| Female | 0 | 1.9 | nc | (nc-nc) |  | Female | 15 | 10.2 | 147.2 | (82.3-242.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 1.6 | nc | (nc-nc) |  | Male | 73 | 76.2 | 95.9 | (75.1-120.5) |
| Female | 0 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 13 | 13.3 | 97.6 | (51.9-166.9) |  | Male | 10 | 6.1 | 163.7 | (78.4-301.0) |
| Female | 6 | 8.1 | 74.3 | (27.1-161.7) |  | Female | 5 | 3.8 | 130.1 | (41.9-303.5) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 3.7 | nc | (nc-nc) |  | Male | 6 | 2.6 | 232.8 | (85.0-506.6) |
| Female | 2 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 13 | 10.0 | 130.3 | (69.3-222.8) |  | Male | 4 | 5.5 | nc | (nc-nc) |
| Female | 10 | 7.5 | 133.7 | (64.0-246.0) |  | Female | 20 | 15.5 | 128.9 | (78.7-199.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 8.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 3.1 | nc | (nc-nc) |  | Female | 14 | 21.7 | 64.5 | (35.2-108.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 48 | 46.0 | 104.3 | (76.9-138.3) |  | Male | 320 | 319.3 | 100.2 | (89.5-111.8) |
| Female | 38 | 51.7 | 73.4 | (52.0-100.8) |  | Female | 314 | 341.1 | 92.0 | (82.1-102.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

282

# Somerville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 34 | 50.5 | 67.4 | (46.7-94.2) |  | Male | 27 | 36.0 | 74.9 | (49.4-109.0) |
| Female | 17 | 19.0 | 89.3 | (52.0-143.1) |  | Female | 20 | 33.0 | 60.6 | (37.0-93.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 9 | 13.0 | 69.1 | (31.5-131.2) |  | Male | 10 | 10.7 | 93.8 | (44.9-172.5) |
| Female | 11 | 10.2 | 108.0 | (53.8-193.2) |  | Female | 12 | 8.8 | 136.1 | (70.3-237.8) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 35 | 32.4 | 107.9 | (75.2-150.1) |
| Female | 185 | 226.2 | 81.8 | (70.4-94.5) |  | Female | 21 | 28.8 | 73.0 | (45.2-111.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 21 | 25.4 | 82.7 | (51.2-126.4) |
| Female | 11 | 10.0 | 109.9 | (54.8-196.6) |  | Female | 12 | 11.9 | 101.2 | (52.3-176.9) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 51 | 57.6 | 88.6 | (65.9-116.4) |  |  |  |  |  |  |
| Female | 45 | 57.7 | 78.0 | (56.9-104.4) |  | Female | 24 | 19.9 | 120.4 | (77.1-179.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 13 | 13.0 | 100.2 | (53.3-171.4) |  | Male | 18 | 18.2 | 98.9 | (58.6-156.3) |
| Female | 3 | 3.7 | nc | (nc-nc) |  | Female | 19 | 19.3 | 98.6 | (59.3-154.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 9 | 7.9 | 114.0 | (52.0-216.5) |  | Male | 137 | 152.6 | 89.8 | (75.4-106.1) |
| Female | 4 | 6.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 35 | 30.5 | 114.7 | (79.9-159.6) |  | Male | 16 | 12.7 | 126.3 | (72.1-205.1) |
| Female | 22 | 17.9 | 123.1 | (77.1-186.3) |  | Female | 14 | 7.8 | 179.0 | (97.8-300.4) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 9 | 7.6 | 117.9 | (53.8-223.8) |  | Male | 11 | 17.7 | 62.3 | (31.1-111.5) |
| Female | 3 | 2.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 17 | 23.3 | 72.9 | (42.4-116.7) |  | Male | 21 | 18.0 | 116.5 | (72.1-178.1) |
| Female | 17 | 17.6 | 96.3 | (56.1-154.3) |  | Female | 45 | 58.9 | 76.4 | (55.7-102.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 26 | 17.9 | 145.4 | (94.9-213.0) |  |  |  |  |  |  |
| Female | 14 | 6.4 | 220.0 | (120.2-369.1) |  | Female | 49 | 48.6 | 100.9 | (74.6-133.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 115 | 88.8 | 129.5 | (106.9-155.4) |  | Male | 664 | 693.2 | 95.8 | (88.6-103.4) |
| Female | 98 | 99.7 | 98.3 | (79.8-119.8) |  | Female | 705 | 774.7 | 91.0 | (84.4-98.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

283

# South Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 13 | 20.1 | 64.7 | (34.4-110.6) |  | Male | 15 | 12.5 | 120.3 | (67.3-198.4) |
| Female | 12 | 8.0 | 149.7 | (77.3-261.6) |  | Female | 12 | 10.5 | 114.1 | (58.9-199.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 3.5 | nc | (nc-nc) |  | Male | 2 | 4.0 | nc | (nc-nc) |
| Female | 3 | 3.6 | nc | (nc-nc) |  | Female | 2 | 3.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 9 | 11.1 | 81.2 | (37.0-154.1) |
| Female | 96 | 84.1 | 114.2 | (92.5-139.4) |  | Female | 12 | 10.9 | 109.6 | (56.6-191.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 9.1 | 77.3 | (31.0-159.2) |
| Female | 5 | 2.6 | 189.0 | (60.9-441.1) |  | Female | 5 | 4.6 | 109.2 | (35.2-254.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 22 | 21.0 | 104.8 | (65.7-158.7) |  |  |  |  |  |  |
| Female | 32 | 22.8 | 140.3 | (95.9-198.0) |  | Female | 6 | 7.4 | 81.4 | (29.7-177.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 5.1 | nc | (nc-nc) |  | Male | 2 | 7.1 | nc | (nc-nc) |
| Female | 3 | 1.5 | nc | (nc-nc) |  | Female | 9 | 8.1 | 111.3 | (50.8-211.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 54 | 60.9 | 88.6 | (66.6-115.7) |
| Female | 0 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 10.7 | 75.0 | (32.3-147.8) |  | Male | 5 | 4.8 | 104.6 | (33.7-244.0) |
| Female | 8 | 6.9 | 116.1 | (50.0-228.8) |  | Female | 1 | 3.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 3.0 | nc | (nc-nc) |  | Male | 3 | 2.1 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 7.8 | 64.5 | (20.8-150.5) |  | Male | 4 | 4.6 | nc | (nc-nc) |
| Female | 8 | 6.5 | 123.5 | (53.2-243.4) |  | Female | 14 | 15.4 | 91.2 | (49.8-153.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 6.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 2.6 | nc | (nc-nc) |  | Female | 29 | 18.9 | 153.2 | (102.6-220.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 35 | 35.8 | 97.9 | (68.2-136.1) |  | Male | 220 | 252.1 | 87.3 | (76.1-99.6) |
| Female | 36 | 42.2 | 85.4 | (59.8-118.2) |  | Female | 314 | 289.7 | 108.4 | (96.7-121.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

284

# Southampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 8.1 | 74.2 | (27.1-161.5) |  | Male | 0 | 4.8 | nc | (nc-nc) |
| Female | 2 | 2.2 | nc | (nc-nc) |  | Female | 3 | 3.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 0 | 1.6 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 1 | 4.4 | nc | (nc-nc) |
| Female | 24 | 27.3 | 88.0 | (56.4-130.9) |  | Female | 3 | 3.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 3.6 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 8 | 8.4 | 95.4 | (41.1-188.0) |  |  |  |  |  |  |
| Female | 6 | 6.4 | 93.8 | (34.3-204.2) |  | Female | 1 | 2.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 2 | 2.8 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 3 | 2.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.5 | nc | (nc-nc) |  | Male | 20 | 24.0 | 83.2 | (50.8-128.5) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 4.2 | nc | (nc-nc) |  | Male | 4 | 1.9 | nc | (nc-nc) |
| Female | 4 | 2.1 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.1 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 3.1 | nc | (nc-nc) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 2 | 5.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 2.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 7 | 6.2 | 112.2 | (45.0-231.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 7 | 13.6 | 51.4 | (20.6-105.8) |  | Male | 73 | 99.4 | 73.5 | (57.6-92.4) |
| Female | 16 | 12.2 | 131.2 | (75.0-213.1) |  | Female | 78 | 88.0 | 88.7 | (70.1-110.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

285

# Southborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 9 | 9.4 | 95.8 | (43.7-182.0) |  | Male | 9 | 6.3 | 142.4 | (65.0-270.3) |
| Female | 5 | 3.2 | 155.9 | (50.2-363.7) |  | Female | 3 | 4.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 2.0 | nc | (nc-nc) |  | Male | 4 | 2.0 | nc | (nc-nc) |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 0 | 1.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 2 | 5.6 | nc | (nc-nc) |
| Female | 46 | 40.3 | 114.2 | (83.6-152.3) |  | Female | 4 | 4.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 5.1 | 98.8 | (31.8-230.5) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 2 | 2.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 10.9 | 54.8 | (20.0-119.4) |  |  |  |  |  |  |
| Female | 9 | 9.9 | 91.3 | (41.7-173.3) |  | Female | 1 | 3.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.5 | nc | (nc-nc) |  | Male | 1 | 3.5 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 3 | 3.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 28 | 31.6 | 88.5 | (58.8-128.0) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 5.7 | 175.0 | (83.8-321.8) |  | Male | 1 | 2.4 | nc | (nc-nc) |
| Female | 2 | 3.1 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 1.5 | nc | (nc-nc) |  | Male | 3 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 4.0 | nc | (nc-nc) |  | Male | 3 | 2.7 | nc | (nc-nc) |
| Female | 3 | 2.8 | nc | (nc-nc) |  | Female | 6 | 7.8 | 76.9 | (28.1-167.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 3.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 6 | 8.7 | 68.9 | (25.1-149.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 14 | 16.6 | 84.3 | (46.0-141.4) |  | Male | 125 | 128.0 | 97.7 | (81.3-116.4) |
| Female | 12 | 17.3 | 69.2 | (35.7-120.9) |  | Female | 115 | 130.0 | 88.5 | (73.0-106.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

286

# Southbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 17 | 16.1 | 105.7 | (61.5-169.2) |  | Male | 6 | 10.4 | 57.5 | (21.0-125.2) |
| Female | 7 | 6.9 | 101.4 | (40.6-209.0) |  | Female | 4 | 9.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 3.3 | nc | (nc-nc) |  | Male | 6 | 3.3 | 184.3 | (67.3-401.2) |
| Female | 2 | 3.0 | nc | (nc-nc) |  | Female | 4 | 3.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 11 | 9.4 | 117.2 | (58.4-209.7) |
| Female | 58 | 72.6 | 79.9 | (60.7-103.3) |  | Female | 14 | 9.5 | 146.6 | (80.1-246.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 7.7 | 103.7 | (44.7-204.4) |
| Female | 4 | 2.4 | nc | (nc-nc) |  | Female | 0 | 4.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 20 | 17.8 | 112.4 | (68.6-173.6) |  |  |  |  |  |  |
| Female | 20 | 20.3 | 98.8 | (60.3-152.5) |  | Female | 10 | 6.4 | 157.4 | (75.4-289.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 4.1 | nc | (nc-nc) |  | Male | 8 | 5.8 | 139.0 | (59.9-273.9) |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 2 | 7.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 52 | 48.3 | 107.7 | (80.5-141.3) |
| Female | 4 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 9.0 | 88.6 | (38.2-174.7) |  | Male | 6 | 3.9 | 153.3 | (56.0-333.7) |
| Female | 10 | 5.8 | 171.8 | (82.3-316.0) |  | Female | 4 | 2.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 7 | 2.4 | 297.9 | (119.3-613.7) |  | Male | 1 | 2.6 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 6.8 | 102.8 | (41.2-211.8) |  | Male | 2 | 4.3 | nc | (nc-nc) |
| Female | 10 | 5.6 | 177.7 | (85.1-326.8) |  | Female | 10 | 13.1 | 76.2 | (36.5-140.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 8 | 5.6 | 142.3 | (61.3-280.3) |  |  |  |  |  |  |
| Female | 0 | 2.3 | nc | (nc-nc) |  | Female | 19 | 16.4 | 116.0 | (69.8-181.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 49 | 28.1 | 174.5 | (129.1-230.7) |  | Male | 245 | 208.0 | 117.8 | (103.5-133.5) |
| Female | 26 | 34.7 | 75.0 | (49.0-109.9) |  | Female | 231 | 249.5 | 92.6 | (81.0-105.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

287

# Southwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 12 | 10.3 | 116.4 | (60.1-203.3) |  | Male | 6 | 6.7 | 89.5 | (32.7-194.7) |
| Female | 2 | 4.2 | nc | (nc-nc) |  | Female | 3 | 5.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 2.0 | nc | (nc-nc) |  | Male | 1 | 2.2 | nc | (nc-nc) |
| Female | 2 | 1.8 | nc | (nc-nc) |  | Female | 0 | 1.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 2 | 6.1 | nc | (nc-nc) |
| Female | 45 | 44.9 | 100.3 | (73.2-134.3) |  | Female | 6 | 5.8 | 102.7 | (37.5-223.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 5.1 | 98.2 | (31.6-229.2) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 1 | 2.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 11.5 | 61.0 | (24.4-125.7) |  |  |  |  |  |  |
| Female | 15 | 12.5 | 120.0 | (67.1-197.9) |  | Female | 3 | 3.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 2.7 | nc | (nc-nc) |  | Male | 2 | 3.7 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 2 | 4.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 30 | 32.9 | 91.3 | (61.6-130.3) |
| Female | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 5.9 | 168.3 | (80.6-309.6) |  | Male | 2 | 2.5 | nc | (nc-nc) |
| Female | 4 | 3.6 | nc | (nc-nc) |  | Female | 2 | 1.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.6 | nc | (nc-nc) |  | Male | 3 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 4.2 | nc | (nc-nc) |  | Male | 3 | 2.8 | nc | (nc-nc) |
| Female | 5 | 3.3 | 149.5 | (48.2-348.8) |  | Female | 6 | 7.9 | 76.4 | (27.9-166.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 3.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 1.4 | nc | (nc-nc) |  | Female | 9 | 9.9 | 91.2 | (41.6-173.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 19 | 18.3 | 104.0 | (62.6-162.4) |  | Male | 122 | 135.7 | 89.9 | (74.6-107.3) |
| Female | 14 | 21.5 | 65.2 | (35.6-109.4) |  | Female | 128 | 152.7 | 83.8 | (69.9-99.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

288

# Spencer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 22 | 11.9 | 184.7 | (115.7-279.7) |  | Male | 12 | 8.1 | 148.1 | (76.5-258.8) |
| Female | 11 | 4.2 | 262.6 | (130.9-469.8) |  | Female | 5 | 6.0 | 83.3 | (26.9-194.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 2.6 | nc | (nc-nc) |  | Male | 1 | 2.6 | nc | (nc-nc) |
| Female | 2 | 2.0 | nc | (nc-nc) |  | Female | 6 | 1.9 | 308.7 | (112.7-671.8) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 6 | 7.2 | 83.2 | (30.4-181.1) |
| Female | 45 | 49.2 | 91.4 | (66.7-122.3) |  | Female | 9 | 6.0 | 150.1 | (68.5-284.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 11 | 6.5 | 168.3 | (83.9-301.2) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 3 | 2.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 9 | 13.3 | 67.5 | (30.8-128.1) |  |  |  |  |  |  |
| Female | 12 | 12.1 | 99.5 | (51.4-173.9) |  | Female | 1 | 4.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 3.4 | 147.0 | (47.4-343.1) |  | Male | 5 | 4.5 | 112.1 | (36.1-261.6) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 5 | 4.2 | 117.7 | (37.9-274.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 35 | 43.6 | 80.2 | (55.9-111.5) |
| Female | 3 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 7.5 | 133.0 | (63.7-244.7) |  | Male | 1 | 3.0 | nc | (nc-nc) |
| Female | 6 | 3.8 | 157.0 | (57.3-341.7) |  | Female | 2 | 1.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.0 | nc | (nc-nc) |  | Male | 2 | 1.9 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 11 | 5.1 | 216.4 | (107.9-387.2) |  | Male | 2 | 3.5 | nc | (nc-nc) |
| Female | 4 | 3.5 | nc | (nc-nc) |  | Female | 9 | 9.2 | 98.3 | (44.9-186.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 4.7 | 127.6 | (46.6-277.7) |  |  |  |  |  |  |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 17 | 11.2 | 152.2 | (88.6-243.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 34 | 22.2 | 153.5 | (106.3-214.5) |  | Male | 188 | 167.6 | 112.2 | (96.7-129.4) |
| Female | 25 | 22.4 | 111.7 | (72.3-164.9) |  | Female | 182 | 162.0 | 112.3 | (96.6-129.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

289

# Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 87 | 118.9 | 73.1 | (58.6-90.2) |  | Male | 28 | 78.8 | 35.5 | (23.6-51.3) |
| Female | 40 | 47.2 | 84.7 | (60.5-115.3) |  | Female | 26 | 71.0 | 36.6 | (23.9-53.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 31 | 27.0 | 114.6 | (77.9-162.7) |  | Male | 22 | 24.9 | 88.2 | (55.3-133.6) |
| Female | 21 | 24.1 | 87.1 | (53.9-133.1) |  | Female | 29 | 21.8 | 133.0 | (89.0-191.0) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 7 | 4.2 | 166.7 | (66.8-343.4) |  | Male | 76 | 71.5 | 106.3 | (83.7-133.0) |
| Female | 512 | 552.9 | 92.6 | (84.8-101.0) |  | Female | 67 | 68.6 | 97.6 | (75.7-124.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 71 | 59.5 | 119.3 | (93.2-150.5) |
| Female | 42 | 20.0 | 210.2 | (151.5-284.2) |  | Female | 20 | 29.1 | 68.8 | (42.0-106.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 142 | 132.2 | 107.4 | (90.5-126.6) |  |  |  |  |  |  |
| Female | 155 | 140.0 | 110.7 | (94.0-129.6) |  | Female | 40 | 47.8 | 83.6 | (59.7-113.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 33 | 31.4 | 105.2 | (72.4-147.8) |  | Male | 48 | 43.0 | 111.7 | (82.4-148.1) |
| Female | 8 | 9.3 | 85.9 | (37.0-169.2) |  | Female | 51 | 47.8 | 106.6 | (79.4-140.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 14 | 12.1 | 115.5 | (63.1-193.8) |  | Male | 328 | 384.0 | 85.4 | (76.4-95.2) |
| Female | 15 | 10.8 | 138.8 | (77.6-228.9) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 84 | 69.9 | 120.2 | (95.9-148.8) |  | Male | 35 | 29.2 | 119.9 | (83.5-166.8) |
| Female | 55 | 43.7 | 125.8 | (94.8-163.8) |  | Female | 21 | 19.0 | 110.4 | (68.3-168.8) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 17 | 18.3 | 92.9 | (54.1-148.7) |  | Male | 12 | 22.6 | 53.0 | (27.4-92.6) |
| Female | 10 | 6.0 | 166.5 | (79.7-306.3) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 49 | 52.5 | 93.3 | (69.0-123.3) |  | Male | 15 | 34.2 | 43.9 | (24.5-72.4) |
| Female | 39 | 41.7 | 93.6 | (66.6-128.0) |  | Female | 78 | 114.0 | 68.4 | (54.1-85.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 61 | 43.2 | 141.3 | (108.1-181.5) |  |  |  |  |  |  |
| Female | 14 | 16.0 | 87.6 | (47.8-146.9) |  | Female | 115 | 123.1 | 93.5 | (77.2-112.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 240 | 212.5 | 112.9 | (99.1-128.2) |  | Male | 1530 | 1599.2 | 95.7 | (90.9-100.6) |
| Female | 252 | 250.3 | 100.7 | (88.6-113.9) |  | Female | 1763 | 1851.6 | 95.2 | (90.8-99.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

290

# Sterling

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 7.2 | 152.7 | (76.1-273.2) |  | Male | 8 | 5.0 | 161.0 | (69.3-317.2) |
| Female | 4 | 2.8 | nc | (nc-nc) |  | Female | 2 | 4.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.6 | nc | (nc-nc) |  | Male | 4 | 1.6 | nc | (nc-nc) |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 8 | 4.5 | 176.0 | (75.8-346.8) |
| Female | 41 | 35.4 | 115.8 | (83.1-157.1) |  | Female | 1 | 4.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 4.3 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 3 | 1.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 8 | 8.8 | 90.9 | (39.2-179.2) |  |  |  |  |  |  |
| Female | 2 | 8.9 | nc | (nc-nc) |  | Female | 2 | 3.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 2.1 | nc | (nc-nc) |  | Male | 4 | 2.8 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 4 | 3.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 42 | 27.8 | 150.9 | (108.7-204.0) |
| Female | 2 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 4.9 | 164.6 | (70.9-324.3) |  | Male | 1 | 1.8 | nc | (nc-nc) |
| Female | 3 | 2.6 | nc | (nc-nc) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 3.2 | 189.9 | (69.3-413.4) |  | Male | 3 | 2.3 | nc | (nc-nc) |
| Female | 2 | 2.4 | nc | (nc-nc) |  | Female | 7 | 6.7 | 104.1 | (41.7-214.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 10 | 7.6 | 130.8 | (62.6-240.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 10 | 13.2 | 75.9 | (36.4-139.7) |  | Male | 130 | 104.8 | 124.0 | (103.6-147.2) |
| Female | 18 | 14.6 | 123.1 | (72.9-194.6) |  | Female | 112 | 114.0 | 98.3 | (80.9-118.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

291

# Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 3.6 | nc | (nc-nc) |  | Male | 7 | 2.1 | 327.5 | (131.2-674.8) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 6 | 1.6 | 372.7 | (136.1-811.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 10 | 12.9 | 77.3 | (37.0-142.2) |  | Female | 2 | 1.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 3.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 7 | 4.1 | 170.7 | (68.4-351.6) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 3 | 1.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 12 | 10.2 | 118.0 | (60.9-206.2) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 2 | 1.1 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 7 | 2.9 | 243.7 | (97.6-502.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 6.5 | nc | (nc-nc) |  | Male | 40 | 43.2 | 92.5 | (66.1-126.0) |
| Female | 2 | 7.7 | nc | (nc-nc) |  | Female | 48 | 47.6 | 100.8 | (74.3-133.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

292

# Stoneham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 24 | 28.7 | 83.7 | (53.6-124.6) |  | Male | 12 | 17.4 | 68.8 | (35.5-120.2) |
| Female | 10 | 10.1 | 98.7 | (47.2-181.5) |  | Female | 10 | 13.5 | 73.9 | (35.4-135.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 4.9 | 122.3 | (44.7-266.2) |  | Male | 7 | 5.7 | 122.9 | (49.3-253.3) |
| Female | 4 | 4.3 | nc | (nc-nc) |  | Female | 9 | 4.6 | 196.4 | (89.6-372.8) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 17 | 15.6 | 109.0 | (63.5-174.5) |
| Female | 137 | 108.9 | 125.9 | (105.7-148.8) |  | Female | 13 | 14.0 | 92.9 | (49.4-158.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 17 | 12.7 | 133.6 | (77.8-213.9) |
| Female | 4 | 3.5 | nc | (nc-nc) |  | Female | 6 | 5.9 | 101.6 | (37.1-221.1) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 36 | 30.0 | 120.2 | (84.2-166.4) |  |  |  |  |  |  |
| Female | 28 | 29.4 | 95.3 | (63.3-137.7) |  | Female | 14 | 9.5 | 148.1 | (80.9-248.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 7.2 | 69.6 | (22.4-162.3) |  | Male | 6 | 10.0 | 60.3 | (22.0-131.2) |
| Female | 0 | 2.0 | nc | (nc-nc) |  | Female | 14 | 10.4 | 135.1 | (73.8-226.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  | Male | 51 | 86.3 | 59.1 | (44.0-77.7) |
| Female | 2 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 13 | 15.0 | 86.7 | (46.1-148.3) |  | Male | 10 | 6.7 | 148.5 | (71.1-273.0) |
| Female | 9 | 8.7 | 103.4 | (47.2-196.3) |  | Female | 5 | 4.0 | 124.0 | (40.0-289.4) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 4.1 | nc | (nc-nc) |  | Male | 5 | 3.0 | 167.2 | (53.9-390.3) |
| Female | 4 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 17 | 11.0 | 154.9 | (90.2-248.0) |  | Male | 10 | 6.4 | 157.1 | (75.2-288.9) |
| Female | 10 | 8.0 | 124.3 | (59.5-228.5) |  | Female | 26 | 19.1 | 136.0 | (88.8-199.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 9.4 | 74.5 | (29.9-153.6) |  |  |  |  |  |  |
| Female | 9 | 3.3 | 270.4 | (123.4-513.4) |  | Female | 36 | 24.7 | 145.5 | (101.9-201.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 41 | 50.2 | 81.6 | (58.6-110.8) |  | Male | 332 | 355.8 | 93.3 | (83.5-103.9) |
| Female | 54 | 52.4 | 103.1 | (77.4-134.5) |  | Female | 427 | 369.6 | 115.5 | (104.8-127.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

293

# Stoughton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 31 | 32.7 | 94.9 | (64.5-134.7) |  | Male | 16 | 20.4 | 78.5 | (44.8-127.5) |
| Female | 17 | 13.1 | 130.2 | (75.8-208.4) |  | Female | 23 | 17.2 | 133.5 | (84.6-200.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 6.0 | nc | (nc-nc) |  | Male | 9 | 6.7 | 135.3 | (61.7-256.8) |
| Female | 6 | 5.5 | 109.9 | (40.1-239.2) |  | Female | 7 | 5.9 | 118.1 | (47.3-243.3) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 15 | 18.3 | 81.8 | (45.7-134.9) |
| Female | 133 | 139.9 | 95.1 | (79.6-112.7) |  | Female | 26 | 18.0 | 144.2 | (94.1-211.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 11 | 15.1 | 72.9 | (36.3-130.4) |
| Female | 2 | 4.5 | nc | (nc-nc) |  | Female | 3 | 7.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 35 | 34.5 | 101.5 | (70.7-141.1) |  |  |  |  |  |  |
| Female | 39 | 37.9 | 102.9 | (73.2-140.7) |  | Female | 14 | 12.1 | 115.5 | (63.1-193.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 11 | 8.4 | 130.9 | (65.3-234.3) |  | Male | 13 | 11.6 | 111.9 | (59.5-191.4) |
| Female | 5 | 2.6 | 195.5 | (63.0-456.3) |  | Female | 20 | 13.4 | 149.2 | (91.1-230.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 2.3 | nc | (nc-nc) |  | Male | 97 | 103.5 | 93.7 | (76.0-114.3) |
| Female | 6 | 1.9 | 316.2 | (115.5-688.2) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 25 | 17.8 | 140.5 | (90.9-207.4) |  | Male | 9 | 7.8 | 115.2 | (52.6-218.6) |
| Female | 17 | 11.2 | 151.8 | (88.4-243.1) |  | Female | 6 | 5.2 | 116.2 | (42.4-252.8) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 9 | 4.9 | 183.7 | (83.8-348.7) |  | Male | 6 | 3.9 | 152.5 | (55.7-332.0) |
| Female | 2 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 12 | 12.9 | 92.8 | (47.9-162.1) |  | Male | 9 | 7.8 | 115.9 | (52.9-220.0) |
| Female | 8 | 10.4 | 77.2 | (33.2-152.1) |  | Female | 27 | 24.2 | 111.4 | (73.4-162.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 12 | 11.2 | 107.0 | (55.2-187.0) |  |  |  |  |  |  |
| Female | 2 | 4.3 | nc | (nc-nc) |  | Female | 22 | 31.9 | 69.0 | (43.2-104.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 62 | 58.2 | 106.5 | (81.7-136.6) |  | Male | 429 | 418.5 | 102.5 | (93.0-112.7) |
| Female | 59 | 67.5 | 87.4 | (66.6-112.8) |  | Female | 494 | 475.1 | 104.0 | (95.0-113.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

294

# Stow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 16 | 8.2 | 195.3 | (111.6-317.3) |  | Male | 4 | 5.2 | nc | (nc-nc) |
| Female | 3 | 2.3 | nc | (nc-nc) |  | Female | 3 | 3.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 1 | 1.7 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 4 | 1.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 2 | 4.7 | nc | (nc-nc) |
| Female | 28 | 30.0 | 93.3 | (62.0-134.9) |  | Female | 4 | 3.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 3.9 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 1 | 1.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 9 | 9.0 | 100.2 | (45.7-190.2) |  |  |  |  |  |  |
| Female | 8 | 6.7 | 119.7 | (51.5-235.9) |  | Female | 5 | 2.5 | 200.1 | (64.5-466.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.1 | nc | (nc-nc) |  | Male | 2 | 3.0 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 3 | 2.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 30 | 26.0 | 115.4 | (77.8-164.7) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 4.6 | nc | (nc-nc) |  | Male | 1 | 2.0 | nc | (nc-nc) |
| Female | 2 | 2.3 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.2 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 3.3 | nc | (nc-nc) |  | Male | 3 | 2.0 | nc | (nc-nc) |
| Female | 2 | 1.9 | nc | (nc-nc) |  | Female | 7 | 5.5 | 127.1 | (50.9-261.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 9 | 7.0 | 128.9 | (58.8-244.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 7 | 14.5 | 48.2 | (19.3-99.2) |  | Male | 96 | 106.1 | 90.5 | (73.3-110.5) |
| Female | 10 | 12.8 | 78.0 | (37.4-143.5) |  | Female | 103 | 94.8 | 108.7 | (88.7-131.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

295

# Sturbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 17 | 10.6 | 160.2 | (93.3-256.5) |  | Male | 9 | 6.8 | 132.3 | (60.4-251.2) |
| Female | 5 | 3.7 | 134.6 | (43.4-314.1) |  | Female | 8 | 5.2 | 153.1 | (65.9-301.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 3 | 2.2 | nc | (nc-nc) |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 2 | 1.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 8 | 6.1 | 132.0 | (56.9-260.2) |
| Female | 38 | 43.0 | 88.4 | (62.5-121.3) |  | Female | 4 | 5.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 5.2 | 95.8 | (30.9-223.6) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 2 | 2.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 8 | 11.5 | 69.5 | (29.9-136.9) |  |  |  |  |  |  |
| Female | 10 | 10.9 | 91.9 | (44.0-169.0) |  | Female | 2 | 3.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 2.8 | nc | (nc-nc) |  | Male | 4 | 3.9 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 7 | 3.8 | 183.8 | (73.6-378.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 0.7 | nc | (nc-nc) |  | Male | 39 | 35.4 | 110.2 | (78.3-150.6) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 6.1 | 98.6 | (36.0-214.6) |  | Male | 2 | 2.6 | nc | (nc-nc) |
| Female | 2 | 3.4 | nc | (nc-nc) |  | Female | 1 | 1.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.7 | nc | (nc-nc) |  | Male | 2 | 1.1 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 4.3 | 116.3 | (37.5-271.5) |  | Male | 0 | 2.6 | nc | (nc-nc) |
| Female | 2 | 3.0 | nc | (nc-nc) |  | Female | 5 | 7.9 | 63.2 | (20.4-147.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 3.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 18 | 9.6 | 187.0 | (110.8-295.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 21 | 19.4 | 108.3 | (67.0-165.5) |  | Male | 151 | 140.1 | 107.8 | (91.3-126.4) |
| Female | 14 | 19.8 | 70.8 | (38.7-118.8) |  | Female | 135 | 142.2 | 95.0 | (79.6-112.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

296

# Sudbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 14 | 19.2 | 73.0 | (39.9-122.5) |  | Male | 17 | 12.8 | 133.1 | (77.5-213.1) |
| Female | 1 | 6.3 | nc | (nc-nc) |  | Female | 9 | 9.3 | 96.6 | (44.1-183.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 4.0 | 175.2 | (70.2-361.0) |  | Male | 5 | 4.2 | 119.9 | (38.6-279.8) |
| Female | 5 | 3.1 | 163.8 | (52.8-382.2) |  | Female | 3 | 3.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 7 | 11.4 | 61.5 | (24.6-126.7) |
| Female | 118 | 79.4 | 148.6 | (123.0-178.0) |  | Female | 14 | 9.3 | 151.2 | (82.6-253.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 10.3 | nc | (nc-nc) |
| Female | 0 | 2.6 | nc | (nc-nc) |  | Female | 5 | 4.0 | 124.5 | (40.1-290.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 27 | 21.5 | 125.6 | (82.7-182.7) |  |  |  |  |  |  |
| Female | 13 | 19.1 | 68.1 | (36.2-116.5) |  | Female | 9 | 6.7 | 135.2 | (61.7-256.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 5.4 | nc | (nc-nc) |  | Male | 9 | 7.1 | 126.0 | (57.5-239.2) |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 4 | 6.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 67 | 68.3 | 98.1 | (76.0-124.6) |
| Female | 1 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 9 | 11.8 | 76.1 | (34.7-144.4) |  | Male | 3 | 4.8 | nc | (nc-nc) |
| Female | 6 | 6.0 | 99.3 | (36.3-216.3) |  | Female | 3 | 2.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 3.2 | nc | (nc-nc) |  | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 8.0 | 87.0 | (34.8-179.2) |  | Male | 7 | 5.3 | 133.0 | (53.3-274.1) |
| Female | 5 | 5.3 | 95.0 | (30.6-221.7) |  | Female | 19 | 14.4 | 132.2 | (79.5-206.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 7.4 | 67.1 | (21.6-156.7) |  |  |  |  |  |  |
| Female | 1 | 2.2 | nc | (nc-nc) |  | Female | 18 | 17.8 | 101.2 | (59.9-160.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 13 | 35.8 | 36.3 | (19.3-62.1) |  | Male | 223 | 264.5 | 84.3 | (73.6-96.1) |
| Female | 29 | 34.0 | 85.4 | (57.2-122.6) |  | Female | 292 | 253.8 | 115.0 | (102.2-129.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

297

# Sunderland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 3.2 | nc | (nc-nc) |  | Male | 1 | 2.1 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 1.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 1.9 | nc | (nc-nc) |
| Female | 17 | 10.4 | 163.1 | (95.0-261.2) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 1.6 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 3.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 2.5 | nc | (nc-nc) |  | Female | 2 | 0.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 8 | 10.4 | 77.2 | (33.3-152.2) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 2 | 2.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 3 | 2.3 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 5.5 | nc | (nc-nc) |  | Male | 32 | 42.8 | 74.7 | (51.1-105.5) |
| Female | 3 | 4.4 | nc | (nc-nc) |  | Female | 34 | 34.7 | 97.9 | (67.8-136.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

298

# Sutton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 13 | 10.0 | 130.2 | (69.2-222.6) |  | Male | 10 | 6.5 | 152.8 | (73.1-281.0) |
| Female | 5 | 2.5 | 196.8 | (63.4-459.2) |  | Female | 7 | 4.3 | 161.6 | (64.7-333.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 4 | 2.1 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 2 | 1.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 9 | 5.9 | 152.3 | (69.5-289.2) |
| Female | 38 | 36.6 | 103.7 | (73.4-142.4) |  | Female | 3 | 4.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 5.3 | nc | (nc-nc) |
| Female | 3 | 1.3 | nc | (nc-nc) |  | Female | 2 | 1.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 11.3 | 53.0 | (19.4-115.4) |  |  |  |  |  |  |
| Female | 8 | 7.8 | 103.0 | (44.3-202.9) |  | Female | 1 | 3.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 2.7 | nc | (nc-nc) |  | Male | 2 | 3.7 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 1 | 2.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 30 | 34.2 | 87.7 | (59.2-125.3) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 9 | 6.1 | 147.8 | (67.5-280.7) |  | Male | 2 | 2.5 | nc | (nc-nc) |
| Female | 5 | 2.7 | 187.1 | (60.3-436.7) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  | Male | 4 | 1.1 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 4.1 | 193.0 | (83.1-380.3) |  | Male | 6 | 2.7 | 222.5 | (81.2-484.3) |
| Female | 4 | 2.2 | nc | (nc-nc) |  | Female | 7 | 7.5 | 93.8 | (37.6-193.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 3.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 12 | 8.3 | 144.3 | (74.5-252.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 20 | 18.1 | 110.6 | (67.5-170.8) |  | Male | 141 | 135.1 | 104.4 | (87.8-123.1) |
| Female | 14 | 14.2 | 98.5 | (53.8-165.3) |  | Female | 124 | 113.1 | 109.6 | (91.2-130.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

299

# Swampscott

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 29 | 16.9 | 171.4 | (114.8-246.2) |  | Male | 14 | 10.4 | 134.4 | (73.4-225.5) |
| Female | 13 | 6.2 | 208.7 | (111.0-356.9) |  | Female | 16 | 8.4 | 190.0 | (108.5-308.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 3.1 | nc | (nc-nc) |  | Male | 1 | 3.4 | nc | (nc-nc) |
| Female | 1 | 2.7 | nc | (nc-nc) |  | Female | 4 | 2.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 14 | 9.4 | 149.5 | (81.6-250.8) |
| Female | 76 | 68.8 | 110.5 | (87.1-138.3) |  | Female | 12 | 8.7 | 138.2 | (71.3-241.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 7.8 | 64.0 | (20.6-149.4) |
| Female | 3 | 2.2 | nc | (nc-nc) |  | Female | 4 | 3.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 17 | 18.2 | 93.6 | (54.5-149.9) |  |  |  |  |  |  |
| Female | 19 | 18.2 | 104.2 | (62.7-162.8) |  | Female | 4 | 5.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 4.3 | nc | (nc-nc) |  | Male | 6 | 6.0 | 100.4 | (36.7-218.5) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 5 | 6.4 | 78.6 | (25.3-183.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 56 | 51.7 | 108.3 | (81.8-140.7) |
| Female | 4 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 9.1 | 109.8 | (52.6-202.0) |  | Male | 3 | 4.0 | nc | (nc-nc) |
| Female | 4 | 5.4 | nc | (nc-nc) |  | Female | 2 | 2.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.4 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 6.8 | 74.0 | (23.9-172.8) |  | Male | 5 | 3.9 | 129.0 | (41.6-301.1) |
| Female | 11 | 4.9 | 222.5 | (110.9-398.1) |  | Female | 20 | 12.1 | 165.2 | (100.9-255.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 5.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 2.0 | nc | (nc-nc) |  | Female | 20 | 15.4 | 129.5 | (79.1-200.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 27 | 29.4 | 91.9 | (60.5-133.7) |  | Male | 225 | 213.2 | 105.5 | (92.2-120.3) |
| Female | 32 | 32.4 | 98.7 | (67.5-139.4) |  | Female | 273 | 230.5 | 118.4 | (104.8-133.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

300

# Swansea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 21 | 18.8 | 111.9 | (69.3-171.1) |  | Male | 12 | 12.1 | 98.8 | (51.0-172.5) |
| Female | 12 | 7.4 | 162.7 | (83.9-284.1) |  | Female | 6 | 10.0 | 60.3 | (22.0-131.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 3.6 | 194.3 | (77.8-400.3) |  | Male | 4 | 3.9 | nc | (nc-nc) |
| Female | 4 | 3.1 | nc | (nc-nc) |  | Female | 4 | 3.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 14 | 10.9 | 129.0 | (70.4-216.4) |
| Female | 65 | 84.2 | 77.2 | (59.6-98.4) |  | Female | 10 | 10.2 | 97.6 | (46.7-179.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 9.3 | 64.5 | (23.6-140.4) |
| Female | 3 | 2.6 | nc | (nc-nc) |  | Female | 4 | 4.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 20 | 20.2 | 98.8 | (60.4-152.7) |  |  |  |  |  |  |
| Female | 18 | 21.2 | 84.9 | (50.3-134.2) |  | Female | 4 | 7.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 5.0 | nc | (nc-nc) |  | Male | 8 | 6.8 | 116.8 | (50.3-230.2) |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 8 | 7.5 | 106.9 | (46.0-210.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 1.3 | nc | (nc-nc) |  | Male | 81 | 64.0 | 126.6 | (100.6-157.4) |
| Female | 1 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 20 | 10.9 | 183.0 | (111.7-282.6) |  | Male | 4 | 4.6 | nc | (nc-nc) |
| Female | 5 | 6.6 | 75.3 | (24.3-175.8) |  | Female | 5 | 2.9 | 174.3 | (56.2-406.6) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 3.0 | nc | (nc-nc) |  | Male | 5 | 2.3 | 216.8 | (69.9-506.0) |
| Female | 2 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 7.5 | nc | (nc-nc) |  | Male | 5 | 4.8 | 103.1 | (33.2-240.7) |
| Female | 5 | 5.7 | 87.2 | (28.1-203.4) |  | Female | 12 | 14.4 | 83.2 | (43.0-145.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 6.8 | 88.0 | (32.2-191.6) |  |  |  |  |  |  |
| Female | 2 | 2.4 | nc | (nc-nc) |  | Female | 14 | 18.9 | 74.1 | (40.5-124.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 33 | 34.5 | 95.7 | (65.9-134.4) |  | Male | 286 | 250.3 | 114.3 | (101.4-128.3) |
| Female | 37 | 39.9 | 92.8 | (65.3-127.9) |  | Female | 240 | 277.2 | 86.6 | (76.0-98.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

301

# Taunton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 52 | 55.1 | 94.4 | (70.5-123.8) |  | Male | 23 | 36.6 | 62.8 | (39.8-94.2) |
| Female | 27 | 21.8 | 123.8 | (81.6-180.2) |  | Female | 25 | 30.8 | 81.1 | (52.5-119.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 12 | 11.5 | 104.6 | (54.0-182.7) |  | Male | 9 | 11.8 | 76.5 | (34.9-145.2) |
| Female | 9 | 9.9 | 91.3 | (41.7-173.3) |  | Female | 14 | 10.0 | 140.2 | (76.6-235.2) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 5 | 2.0 | 252.5 | (81.4-589.2) |  | Male | 37 | 32.8 | 112.9 | (79.5-155.6) |
| Female | 241 | 246.5 | 97.8 | (85.8-110.9) |  | Female | 41 | 30.8 | 133.0 | (95.4-180.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 38 | 28.4 | 133.8 | (94.7-183.7) |
| Female | 8 | 8.5 | 94.6 | (40.7-186.4) |  | Female | 11 | 13.0 | 84.5 | (42.1-151.1) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 69 | 61.1 | 112.9 | (87.8-142.9) |  |  |  |  |  |  |
| Female | 87 | 65.1 | 133.7 | (107.1-165.0) |  | Female | 15 | 21.1 | 71.0 | (39.7-117.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 13 | 15.0 | 86.9 | (46.2-148.5) |  | Male | 17 | 20.2 | 84.0 | (48.9-134.6) |
| Female | 1 | 4.2 | nc | (nc-nc) |  | Female | 26 | 22.4 | 116.2 | (75.9-170.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 8 | 4.6 | 172.2 | (74.2-339.4) |  | Male | 144 | 186.9 | 77.1 | (65.0-90.7) |
| Female | 7 | 3.8 | 183.8 | (73.6-378.8) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 36 | 33.0 | 109.0 | (76.3-150.9) |  | Male | 13 | 13.6 | 95.5 | (50.8-163.3) |
| Female | 19 | 19.4 | 97.8 | (58.9-152.8) |  | Female | 9 | 8.8 | 102.0 | (46.6-193.7) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 15 | 8.8 | 170.2 | (95.2-280.8) |  | Male | 10 | 8.4 | 119.0 | (57.0-218.8) |
| Female | 6 | 2.7 | 224.9 | (82.1-489.5) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 16 | 23.1 | 69.1 | (39.5-112.3) |  | Male | 20 | 15.3 | 130.6 | (79.7-201.7) |
| Female | 14 | 18.1 | 77.3 | (42.2-129.6) |  | Female | 65 | 46.4 | 140.0 | (108.0-178.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 20 | 20.6 | 97.0 | (59.2-149.8) |  |  |  |  |  |  |
| Female | 7 | 7.2 | 97.5 | (39.1-201.0) |  | Female | 47 | 54.5 | 86.2 | (63.3-114.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 134 | 101.0 | 132.6 | (111.1-157.1) |  | Male | 759 | 747.8 | 101.5 | (94.4-109.0) |
| Female | 121 | 113.0 | 107.1 | (88.8-127.9) |  | Female | 853 | 825.1 | 103.4 | (96.6-110.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

302

# Templeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 9 | 9.9 | 90.7 | (41.4-172.2) |  | Male | 6 | 6.3 | 95.1 | (34.7-207.0) |
| Female | 3 | 3.0 | nc | (nc-nc) |  | Female | 1 | 4.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 1.9 | 270.2 | (87.1-630.7) |  | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 3 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 3 | 5.7 | nc | (nc-nc) |
| Female | 25 | 37.0 | 67.6 | (43.7-99.8) |  | Female | 4 | 4.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 5.0 | nc | (nc-nc) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 1 | 1.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 9 | 10.9 | 82.2 | (37.5-156.1) |  |  |  |  |  |  |
| Female | 12 | 8.8 | 135.7 | (70.1-237.1) |  | Female | 5 | 3.1 | 160.0 | (51.6-373.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.7 | nc | (nc-nc) |  | Male | 3 | 3.6 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 4 | 3.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 20 | 34.9 | 57.3 | (35.0-88.5) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 9 | 5.8 | 154.6 | (70.5-293.4) |  | Male | 2 | 2.4 | nc | (nc-nc) |
| Female | 2 | 2.9 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 4.0 | nc | (nc-nc) |  | Male | 2 | 2.5 | nc | (nc-nc) |
| Female | 2 | 2.5 | nc | (nc-nc) |  | Female | 5 | 6.7 | 74.6 | (24.1-174.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 3.6 | 137.1 | (44.2-320.0) |  |  |  |  |  |  |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 10 | 8.3 | 120.1 | (57.5-220.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 19 | 17.7 | 107.6 | (64.7-168.0) |  | Male | 108 | 133.0 | 81.2 | (66.6-98.1) |
| Female | 24 | 17.0 | 141.3 | (90.5-210.3) |  | Female | 112 | 119.6 | 93.6 | (77.1-112.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

303

# Tewksbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 40 | 32.1 | 124.6 | (89.0-169.7) |  | Male | 16 | 21.1 | 75.8 | (43.3-123.2) |
| Female | 13 | 12.6 | 103.3 | (55.0-176.7) |  | Female | 16 | 17.1 | 93.7 | (53.5-152.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 9 | 6.4 | 141.1 | (64.4-267.8) |  | Male | 3 | 6.7 | nc | (nc-nc) |
| Female | 6 | 5.4 | 110.6 | (40.4-240.7) |  | Female | 5 | 5.7 | 87.9 | (28.3-205.2) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.1 | nc | (nc-nc) |  | Male | 18 | 18.7 | 96.2 | (57.0-152.1) |
| Female | 143 | 139.8 | 102.3 | (86.2-120.5) |  | Female | 18 | 17.5 | 103.0 | (61.0-162.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 15 | 16.3 | 92.3 | (51.6-152.2) |
| Female | 8 | 4.5 | 176.8 | (76.1-348.3) |  | Female | 10 | 7.4 | 136.0 | (65.1-250.1) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 34 | 35.6 | 95.5 | (66.1-133.5) |  |  |  |  |  |  |
| Female | 34 | 36.7 | 92.6 | (64.2-129.5) |  | Female | 16 | 12.0 | 133.7 | (76.4-217.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 13 | 8.6 | 151.9 | (80.8-259.7) |  | Male | 15 | 11.7 | 128.1 | (71.7-211.3) |
| Female | 4 | 2.5 | nc | (nc-nc) |  | Female | 11 | 12.8 | 86.2 | (43.0-154.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 2.5 | nc | (nc-nc) |  | Male | 101 | 106.2 | 95.1 | (77.4-115.5) |
| Female | 4 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 29 | 18.8 | 154.4 | (103.4-221.8) |  | Male | 8 | 7.9 | 101.3 | (43.6-199.7) |
| Female | 13 | 11.1 | 117.2 | (62.3-200.4) |  | Female | 4 | 5.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 5 | 5.0 | 99.2 | (32.0-231.4) |  | Male | 5 | 4.4 | 114.5 | (36.9-267.3) |
| Female | 0 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 23 | 13.1 | 175.5 | (111.2-263.3) |  | Male | 9 | 8.6 | 105.0 | (47.9-199.3) |
| Female | 15 | 10.1 | 149.1 | (83.4-246.0) |  | Female | 26 | 25.0 | 104.1 | (68.0-152.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 8 | 11.8 | 67.6 | (29.1-133.3) |  |  |  |  |  |  |
| Female | 1 | 4.1 | nc | (nc-nc) |  | Female | 26 | 30.8 | 84.4 | (55.1-123.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 70 | 58.7 | 119.2 | (92.9-150.6) |  | Male | 456 | 428.6 | 106.4 | (96.9-116.6) |
| Female | 81 | 66.5 | 121.8 | (96.7-151.4) |  | Female | 498 | 467.7 | 106.5 | (97.3-116.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

304

# Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 3.4 | 146.4 | (47.2-341.7) |  | Male | 8 | 2.4 | 327.8 | (141.1-645.9) |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 7 | 2.2 | 313.3 | (125.5-645.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 2.2 | nc | (nc-nc) |
| Female | 27 | 18.9 | 143.0 | (94.2-208.0) |  | Female | 2 | 2.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 1.9 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 2 | 1.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 4.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 4.3 | nc | (nc-nc) |  | Female | 2 | 1.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 5 | 1.3 | 384.2 | (123.8-896.7) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 2 | 1.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 15 | 12.5 | 120.3 | (67.3-198.5) |
| Female | 1 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 2.2 | nc | (nc-nc) |  | Male | 3 | 0.9 | nc | (nc-nc) |
| Female | 2 | 1.5 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 1.5 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 2 | 3.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 3 | 4.5 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 6.4 | nc | (nc-nc) |  | Male | 61 | 49.3 | 123.6 | (94.5-158.8) |
| Female | 12 | 8.6 | 139.8 | (72.2-244.3) |  | Female | 74 | 61.1 | 121.1 | (95.1-152.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

305

# Tolland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 2 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 2.5 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 2.8 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 10 | 10.6 | 94.3 | (45.1-173.4) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 3 | 7.8 | nc | (nc-nc) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

306

# Topsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 8.6 | nc | (nc-nc) |  | Male | 5 | 5.3 | 95.1 | (30.6-221.8) |
| Female | 4 | 2.8 | nc | (nc-nc) |  | Female | 5 | 3.7 | 136.5 | (44.0-318.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 1.5 | nc | (nc-nc) |  | Male | 0 | 1.7 | nc | (nc-nc) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 2 | 1.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 6 | 4.7 | 127.2 | (46.4-276.9) |
| Female | 28 | 30.7 | 91.2 | (60.6-131.8) |  | Female | 4 | 3.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 3.9 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 2 | 1.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 9.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 8.4 | nc | (nc-nc) |  | Female | 5 | 2.6 | 190.1 | (61.3-443.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 2.2 | nc | (nc-nc) |  | Male | 1 | 3.0 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 2.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 32 | 26.7 | 120.0 | (82.1-169.4) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 4.6 | 108.1 | (34.8-252.3) |  | Male | 2 | 2.0 | nc | (nc-nc) |
| Female | 2 | 2.4 | nc | (nc-nc) |  | Female | 2 | 1.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 2 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 3.3 | nc | (nc-nc) |  | Male | 2 | 1.9 | nc | (nc-nc) |
| Female | 2 | 2.2 | nc | (nc-nc) |  | Female | 3 | 5.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 7 | 6.7 | 103.8 | (41.6-213.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 14 | 15.4 | 91.2 | (49.8-153.0) |  | Male | 93 | 108.2 | 86.0 | (69.4-105.3) |
| Female | 16 | 14.6 | 109.4 | (62.5-177.7) |  | Female | 99 | 103.2 | 95.9 | (78.0-116.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

307

# Townsend

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 14 | 7.2 | 194.5 | (106.2-326.3) |  | Male | 4 | 5.3 | nc | (nc-nc) |
| Female | 3 | 2.5 | nc | (nc-nc) |  | Female | 9 | 4.3 | 208.4 | (95.1-395.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  | Male | 1 | 1.7 | nc | (nc-nc) |
| Female | 3 | 1.4 | nc | (nc-nc) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 8 | 4.8 | 167.3 | (72.0-329.7) |
| Female | 35 | 35.7 | 98.2 | (68.4-136.5) |  | Female | 3 | 4.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 4.7 | 107.4 | (34.6-250.6) |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 4 | 1.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 14 | 8.9 | 158.0 | (86.3-265.1) |  |  |  |  |  |  |
| Female | 14 | 8.0 | 176.0 | (96.1-295.3) |  | Female | 1 | 3.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 2.3 | 353.8 | (152.3-697.1) |  | Male | 2 | 2.9 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 2.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 20 | 31.0 | 64.6 | (39.4-99.8) |
| Female | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 5.3 | 133.0 | (53.3-274.0) |  | Male | 3 | 1.9 | nc | (nc-nc) |
| Female | 5 | 2.7 | 188.4 | (60.7-439.7) |  | Female | 2 | 1.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  | Male | 2 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 3.3 | nc | (nc-nc) |  | Male | 3 | 2.6 | nc | (nc-nc) |
| Female | 5 | 2.3 | 217.4 | (70.1-507.4) |  | Female | 9 | 7.4 | 121.7 | (55.6-231.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 3.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 2 | 8.0 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 15 | 13.9 | 107.8 | (60.3-177.8) |  | Male | 127 | 112.3 | 113.1 | (94.2-134.5) |
| Female | 16 | 14.0 | 114.0 | (65.1-185.1) |  | Female | 123 | 111.5 | 110.3 | (91.6-131.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

308

# Truro

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 3.5 | nc | (nc-nc) |  | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 2 | 1.1 | nc | (nc-nc) |  | Female | 4 | 1.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 16 | 13.2 | 121.5 | (69.4-197.2) |  | Female | 2 | 1.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 1.6 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 3.6 | 140.8 | (45.4-328.6) |  |  |  |  |  |  |
| Female | 4 | 3.1 | nc | (nc-nc) |  | Female | 3 | 1.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 0.9 | nc | (nc-nc) |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 2 | 0.2 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 8 | 12.3 | 65.0 | (28.0-128.2) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 2 | 0.8 | nc | (nc-nc) |  | Female | 1 | 1.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 1 | 3.1 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 6.5 | nc | (nc-nc) |  | Male | 39 | 45.4 | 85.8 | (61.0-117.4) |
| Female | 3 | 6.4 | nc | (nc-nc) |  | Female | 48 | 42.4 | 113.1 | (83.4-150.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

309

# Tyngsborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 9.8 | 61.1 | (22.3-133.1) |  | Male | 4 | 7.2 | nc | (nc-nc) |
| Female | 6 | 3.6 | 169.0 | (61.7-367.8) |  | Female | 6 | 5.8 | 104.2 | (38.0-226.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.3 | nc | (nc-nc) |  | Male | 1 | 2.3 | nc | (nc-nc) |
| Female | 2 | 1.9 | nc | (nc-nc) |  | Female | 2 | 1.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 2 | 6.5 | nc | (nc-nc) |
| Female | 42 | 46.9 | 89.5 | (64.5-121.0) |  | Female | 2 | 5.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 6.1 | nc | (nc-nc) |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 2 | 2.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 12.3 | 81.5 | (39.0-149.8) |  |  |  |  |  |  |
| Female | 5 | 11.2 | 44.7 | (14.4-104.2) |  | Female | 3 | 4.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 2.9 | 171.9 | (55.4-401.3) |  | Male | 3 | 3.9 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 3.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 35 | 38.0 | 92.1 | (64.2-128.1) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 6.8 | 102.5 | (41.1-211.2) |  | Male | 4 | 2.6 | nc | (nc-nc) |
| Female | 2 | 3.5 | nc | (nc-nc) |  | Female | 1 | 1.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  | Male | 0 | 1.8 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 4.4 | 136.8 | (50.0-297.8) |  | Male | 1 | 3.4 | nc | (nc-nc) |
| Female | 3 | 3.2 | nc | (nc-nc) |  | Female | 7 | 9.5 | 74.0 | (29.7-152.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 4.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 11 | 10.4 | 105.8 | (52.8-189.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 22 | 18.4 | 119.5 | (74.9-181.0) |  | Male | 127 | 147.1 | 86.3 | (72.0-102.7) |
| Female | 20 | 18.8 | 106.3 | (64.9-164.2) |  | Female | 127 | 149.5 | 85.0 | (70.8-101.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

310

# Tyringham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 4 | 3.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 1 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 3.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 1 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  | Male | 3 | 12.1 | nc | (nc-nc) |
| Female | 0 | 1.9 | nc | (nc-nc) |  | Female | 7 | 11.4 | 61.4 | (24.6-126.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

311

# Upton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 9 | 7.1 | 127.1 | (58.0-241.3) |  | Male | 7 | 5.0 | 140.8 | (56.4-290.2) |
| Female | 1 | 2.4 | nc | (nc-nc) |  | Female | 3 | 3.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 3 | 1.6 | nc | (nc-nc) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 5 | 4.4 | 112.6 | (36.3-262.8) |
| Female | 35 | 30.9 | 113.2 | (78.8-157.4) |  | Female | 4 | 3.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 4.2 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 2 | 1.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 8.4 | 71.8 | (26.2-156.4) |  |  |  |  |  |  |
| Female | 3 | 7.1 | nc | (nc-nc) |  | Female | 4 | 2.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 2.1 | nc | (nc-nc) |  | Male | 2 | 2.7 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 4 | 2.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 25 | 26.7 | 93.7 | (60.6-138.3) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 4.7 | nc | (nc-nc) |  | Male | 1 | 1.8 | nc | (nc-nc) |
| Female | 1 | 2.4 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 3.1 | 161.3 | (52.0-376.4) |  | Male | 0 | 2.2 | nc | (nc-nc) |
| Female | 2 | 2.0 | nc | (nc-nc) |  | Female | 6 | 6.0 | 99.3 | (36.3-216.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 3.0 | 233.0 | (93.4-480.1) |  |  |  |  |  |  |
| Female | 2 | 0.8 | nc | (nc-nc) |  | Female | 12 | 6.8 | 175.5 | (90.6-306.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 10 | 13.1 | 76.1 | (36.5-140.0) |  | Male | 96 | 102.4 | 93.8 | (76.0-114.5) |
| Female | 16 | 13.3 | 120.7 | (68.9-196.0) |  | Female | 106 | 98.4 | 107.7 | (88.2-130.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

312

# Uxbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 15 | 11.1 | 135.5 | (75.8-223.5) |  | Male | 14 | 7.9 | 176.1 | (96.2-295.5) |
| Female | 2 | 4.9 | nc | (nc-nc) |  | Female | 5 | 7.1 | 70.0 | (22.5-163.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 2.6 | nc | (nc-nc) |  | Male | 3 | 2.6 | nc | (nc-nc) |
| Female | 2 | 2.3 | nc | (nc-nc) |  | Female | 3 | 2.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 8 | 7.1 | 112.1 | (48.3-220.9) |
| Female | 61 | 60.0 | 101.6 | (77.7-130.6) |  | Female | 6 | 7.1 | 84.3 | (30.8-183.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 11 | 6.5 | 168.7 | (84.1-301.8) |
| Female | 1 | 2.0 | nc | (nc-nc) |  | Female | 1 | 3.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 16 | 13.2 | 121.4 | (69.4-197.2) |  |  |  |  |  |  |
| Female | 13 | 14.8 | 87.6 | (46.6-149.7) |  | Female | 6 | 5.1 | 118.6 | (43.3-258.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 3.2 | nc | (nc-nc) |  | Male | 3 | 4.3 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 3 | 5.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 52 | 41.6 | 125.1 | (93.4-164.0) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 13 | 7.5 | 174.5 | (92.8-298.4) |  | Male | 4 | 2.9 | nc | (nc-nc) |
| Female | 3 | 4.6 | nc | (nc-nc) |  | Female | 0 | 2.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 4 | 2.1 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 4.9 | 142.3 | (57.0-293.3) |  | Male | 1 | 3.7 | nc | (nc-nc) |
| Female | 5 | 4.1 | 122.1 | (39.3-284.9) |  | Female | 10 | 11.1 | 90.2 | (43.2-165.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 4.7 | 105.7 | (34.1-246.6) |  |  |  |  |  |  |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 12 | 13.2 | 90.7 | (46.8-158.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 30 | 20.8 | 144.2 | (97.3-205.9) |  | Male | 212 | 162.5 | 130.5 | (113.5-149.3) |
| Female | 25 | 26.5 | 94.3 | (61.0-139.3) |  | Female | 178 | 194.7 | 91.4 | (78.5-105.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

313

# Wakefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 33 | 30.4 | 108.7 | (74.8-152.6) |  | Male | 22 | 19.5 | 113.1 | (70.8-171.2) |
| Female | 9 | 9.3 | 96.5 | (44.0-183.2) |  | Female | 22 | 13.9 | 158.7 | (99.4-240.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 9 | 5.8 | 155.6 | (71.0-295.3) |  | Male | 3 | 6.3 | nc | (nc-nc) |
| Female | 7 | 4.4 | 159.7 | (64.0-329.0) |  | Female | 3 | 4.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 11 | 17.2 | 63.9 | (31.8-114.3) |
| Female | 128 | 111.9 | 114.4 | (95.4-136.0) |  | Female | 14 | 13.5 | 103.6 | (56.6-173.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 13 | 14.2 | 91.6 | (48.7-156.7) |
| Female | 3 | 3.9 | nc | (nc-nc) |  | Female | 6 | 5.8 | 103.3 | (37.7-224.9) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 31 | 32.1 | 96.6 | (65.6-137.1) |  |  |  |  |  |  |
| Female | 27 | 27.9 | 96.7 | (63.7-140.7) |  | Female | 6 | 9.6 | 62.8 | (22.9-136.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 7.8 | 89.5 | (35.9-184.4) |  | Male | 7 | 10.8 | 64.8 | (26.0-133.5) |
| Female | 0 | 1.9 | nc | (nc-nc) |  | Female | 11 | 9.6 | 115.1 | (57.4-206.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 2.2 | nc | (nc-nc) |  | Male | 61 | 93.0 | 65.6 | (50.2-84.3) |
| Female | 0 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 9 | 16.8 | 53.7 | (24.5-101.9) |  | Male | 5 | 7.3 | 68.2 | (22.0-159.2) |
| Female | 12 | 8.6 | 138.9 | (71.7-242.7) |  | Female | 2 | 3.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 4.6 | nc | (nc-nc) |  | Male | 2 | 4.0 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 11 | 12.2 | 90.2 | (45.0-161.4) |  | Male | 5 | 7.6 | 65.9 | (21.2-153.8) |
| Female | 6 | 7.8 | 76.6 | (28.0-166.7) |  | Female | 23 | 21.5 | 107.1 | (67.9-160.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 10.6 | 56.8 | (20.7-123.5) |  |  |  |  |  |  |
| Female | 3 | 3.2 | nc | (nc-nc) |  | Female | 25 | 25.1 | 99.7 | (64.5-147.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 42 | 55.0 | 76.3 | (55.0-103.2) |  | Male | 309 | 389.7 | 79.3 | (70.7-88.6) |
| Female | 61 | 49.3 | 123.7 | (94.6-158.9) |  | Female | 398 | 367.0 | 108.5 | (98.1-119.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

314

# Wales

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 2.7 | nc | (nc-nc) |  | Male | 0 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 2 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.5 | nc | (nc-nc) |
| Female | 10 | 8.9 | 112.7 | (54.0-207.4) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 2.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 7 | 2.1 | 325.9 | (130.6-671.5) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 5 | 9.4 | 53.1 | (17.1-123.8) |
| Female | 1 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 1.5 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 1.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 6 | 2.1 | 279.3 | (102.0-608.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 4.9 | nc | (nc-nc) |  | Male | 22 | 35.5 | 62.1 | (38.9-94.0) |
| Female | 3 | 3.9 | nc | (nc-nc) |  | Female | 33 | 28.8 | 114.7 | (78.9-161.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

315